ARK Files Peptides ETF Targeting GLP-1 and Metabolic Treatments

ARK Investment Management has filed to launch the ARK Peptides ETF, targeting companies involved in the development, manufacturing and distribution of peptide-based therapeutics. The actively managed fund will focus on GLP-1 treatments and next-generation peptide medications addressing obesity, diabetes and metabolic diseases. Its investment universe will extend beyond drug developers to include contract manufacturers expanding production capacity and consumer-facing pharmaceutical distribution platforms. The strategy seeks to capture growth across the peptide therapeutics value chain as demand expands. Exposure will primarily come through total return swaps, supplemented by direct equities and potentially private investments.